相关实验视频
Updated: Jun 1, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
SGLT-2 抑制剂:叙述性审查
Dawood Shehzad1, Muhammad Hasan1, Naveen Rajpurohit2
1Internal Medicine Residency Program, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂提供了除了糖尿病管理之外的显著益处,在治疗心血管和脏疾病方面表现有前途. 它们不断扩大的应用和不断增加的可访问性使它们在现代医学中变得至关重要.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂最初是为了控制2型糖尿病的血糖水平而开发的.
- 新出现的证据突出显示,它们的类效应超出了降血糖的范围.
- 这些影响对心血管和脏健康有重大影响.
研究的目的:
- 审查SGLT2抑制剂的扩展治疗应用.
- 讨论它们在各种非糖尿病疾病中的确立和潜在益处.
- 考虑它们更广泛的使用和可访问性所带来的影响.
主要方法:
- 临床试验和观察性研究的综合文献综述.
- 对SGLT2抑制剂作用背后的药理机制的分析.
- 对心血管,脏和瘤结局数据的评估.
主要成果:
- SGLT2 抑制剂在减少心血管事件和减缓慢性病进展方面表现出强大的疗效.
- 有证据表明,在管理高血压和探索癌症治疗中的应用方面,有潜在的益处.
- 已注意到不良反应和禁忌,但通常是可控的.
结论:
- SGLT2 抑制剂代表了重要的治疗进步,除了糖尿病之外还有广泛的应用.
- 它们对心血管和脏的保护作用已经很成熟,在其他疾病中也有新兴的作用.
- 通过通用药物的可用性来提高可访问性,有望为患者带来更广泛的益处.
相关概念视频
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K

